The need for speed...in phenotypic antimicrobial susceptibility testing

This webinar was recorded live on December 4, 2024.
It is available on demand through December 31, 2025.
Register above for access.

Description

Sepsis remains a top healthcare priority. 48.9 million cases of sepsis occur each year and the average cost per hospital stay for sepsis is double the average cost per stay across all other conditions. Timely and effective antibiotic treatment for sepsis patients is critical. For patients with serious infections (i.e. blood stream infections), reducing time to effective therapy has been associated with decreased mortality. 

There is a delicate balance between timely, broad-spectrum antibiotics and preventing the acceleration of antimicrobial resistance highlighting the need for more rapid phenotypic susceptibility testing. In this webinar, Dr. Linoj Samuel will highlight currently available technology enabling fast phenotypic antimicrobial susceptibility testing (“Fast AST”), potential applications, limitations, and considerations towards implementing novel technology to deliver improved patient outcomes.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, point-of-care coordinators, pathologists, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Explain the applications of fast antimicrobial susceptibility testing (AST) in blood culture workflow.
• Review the current fast AST landscape, available platforms, and technology.
• Discuss implementation strategies of new AST technologies, including potential barriers, considerations, and risks.

Faculty

Linoj Samuel, PhD, D(ABMM)
Division Head, Clinical Microbiology
Henry Ford Health
Detroit, MI

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Linoj Samuel, PhD, D(ABMM)
  • Honorarium/Expenses: Biomerieux
  • Board/Committee Membership/Advisory Board: Cepheid, NextGenDx
  • Grant Research/Support: Biomerieux

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID #4356. This activity was planned in accordance with ACCENT® Standards and Policies.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].